Condition
Shoulder Osteoarthritis: Options and What the Evidence Actually Shows
Glenohumeral OA limits motion and sleep. Injections can help; arthroplasty is definitive for end-stage disease.
Anatomy and clinical context
Cartilage loss in the glenohumeral joint produces pain with elevation and rotation. Cuff integrity changes surgical options (anatomic vs reverse).
Nonoperative care stretches years for many patients before arthroplasty.
Illustration of the shoulder and rotator cuff
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
PT, activity modification, and oral analgesics.
- Step 2
Injections
Corticosteroid and orthobiologic injectates for symptom control.
- Step 3
Surgery
Anatomic or reverse total shoulder arthroplasty for end-stage disease.
Where cell therapy fits
Shoulder OA regenerative data is thinner than knee. Frame injectates as bridges, not cartilage cures.
- Arthroplasty outcomes are generally excellent when indicated.
- Same-day cell products have not shown reliable structural disease modification in large shoulder OA trials.
- Banking younger cells preserves dose options for future protocols.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.